Ann: Noxopharm Investigating Potential COVID-19 Treatment, page-25

Hopefully People are doing a little research behind the claims, I did and things do look quite promising for this treatment type direction. I have looked at early results of the other IL-6 inhibitor studies mentioned in the announcement

Chinese study evidence on Roche's Tocilizumab (which has just gone stage 3 in US) abstract below of 95% positive treatment outcome but remember it is a small study and no mention of Tocilizumab side effects - http://www.chinaxiv.org/abs/202003.00026 (Download the pdf)

"In summary, tocilizumab effectively improve clinical symptoms and repress the deterioration of severe COVID-19 patients. Therefore, Tocilizumab is an effective treatment in severe patients of COVID-19, which provided a new therapeutic strategy for this fatal infectious disease."

Article on IL-6 blocking - https://www.cancernetwork.com/news/anti-il-6-agents-suggested-sitc-treat-patients-covid-19?utm_source=bibblio_recommendation

This comes down to two Questions 1) How well does Phenoxodiol (Idronoxil) perform for anti-inflammatory/cytokine blocking purposes, Especially IL-6 response as can be seen with the promising study in China? and 2) How quickly can clinical trial or human use start for this drug i.e US "right to try" in the current medical environment?

New IP application for "Methods for the treatment of inflammation associated with infection" http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2020900970

At the end of the day though everyone should ignore the noise and decide for themselves, there is high risk involved but high rewards are possible too.